Last $40.49 USD
Change Today +0.01 / 0.02%
Volume 437.2K
CMRX On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 8:10 PM 03/3/15 All times are local (Market data is delayed by at least 15 minutes).

chimerix inc (CMRX) Snapshot

Open
$40.10
Previous Close
$40.48
Day High
$40.80
Day Low
$39.06
52 Week High
02/23/15 - $43.41
52 Week Low
05/20/14 - $14.02
Market Cap
1.6B
Average Volume 10 Days
380.5K
EPS TTM
$-1.56
Shares Outstanding
40.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CHIMERIX INC (CMRX)

chimerix inc (CMRX) Related Businessweek News

View More BusinessWeek News

chimerix inc (CMRX) Details

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel, oral antivirals to address unmet medical needs in the United States. Its lead compounds include brincidofovir (CMX001), which is in Phase III clinical development; CMX157, a nucleotide analog that has completed Phase I study for the treatment of HIV infections. The company’s proprietary lipid technology and chemical library is under discovery and preclinical stage of development. It has collaboration and license agreement with Merck Sharp & Dohme Corp. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

67 Employees
Last Reported Date: 11/7/14
Founded in 2000

chimerix inc (CMRX) Top Compensated Officers

Chief Executive Officer, President, Chief Med...
Total Annual Compensation: $340.0K
Chief Development Officer
Total Annual Compensation: $228.1K
Compensation as of Fiscal Year 2013.

chimerix inc (CMRX) Key Developments

Chimerix, Inc. Provides Update on its Ongoing Phase 3 SUPPRESS Trial

Chimerix, Inc. provided an update on its ongoing Phase 3 SUPPRESS trial. The SUPPRESS trial is evaluating brincidofovir for the prevention of clinically significant cytomegalovirus infection in hematopoietic cell transplant (HCT) recipients. Over 80% of the planned 450 subjects have now been enrolled. The last patient is expected to be enrolled in the summer of 2015 with data anticipated in early 2016. The company had previously anticipated full enrollment of the SUPPRESS trial in early 2015. In addition to the primary endpoint of prevention of CMV infection, SUPPRESS includes a significant number of secondary endpoints to investigate brincidofovir's potential benefits in the setting of HCT. These important secondary endpoints include rates of infections caused by other dsDNA viruses, rates of bacterial and fungal infections that can be associated with CMV reactivation and known side-effects of currently available therapies, hospitalizations, mortality, and assessments of healthcare utilization. Brincidofovir, if approved, will be the first compound indicated for the prevention of CMV infection in HCT recipients, with the potential to show benefits in other infections that negatively impact high-risk HCT recipients. The company believes that the antiviral activity of brincidofovir in preventing and treating multiple dsDNA viruses will be clinically important; more than half of the patients who have enrolled in Chimerix's AdVise trial for the treatment of adenovirus were fighting two or more viral infections.

Chimerix, Inc. Presents Update on Preliminary Data from AdVise Study of Brincidofovir for Adenovirus Infection at BMT Tandem Meetings

Chimerix, Inc. announced the presentation of preliminary data from the open-label, Phase 3 AdVise trial of brincidofovir for adenovirus infection showing a short-term mortality rate of less than 40 percent. The current analysis is based on the first 85 subjects enrolled and supports the trend seen in the first 48 subjects as presented at the meeting of the Infectious Diseases Society of America (IDSA), IDWeek. Historic mortality rates as high as 80% for disseminated adenovirus disease have been reported. These data will be presented at the 2015 BMT Tandem Meetings, the combined annual meetings of the Center for International Blood and Marrow Transplant Research and the American Society of Blood and Marrow Transplantation, taking place in San Diego, CA. Final trial results will be reported at a later date and will comprise clinical outcomes for trial subjects as compared to matched historical controls. Adenovirus is a common virus that leads to upper respiratory or gastrointestinal infections in individuals with a healthy immune system, but it can be rapidly fatal in individuals with a weakened immune system, particularly those who have recently undergone a hematopoietic or bone marrow transplant. There is no approved treatment for adenovirus infection. Brincidofovir is an investigational antiviral that has demonstrated in vitro activity against adenovirus and multiple other DNA viruses. Supportive clinical data on the potential utility of brincidofovir were generated from an expanded access study (Study 350), single-patient experiences, and a Phase 2 dose-ranging study in bone marrow transplant patients with adenovirus infection. The Phase 3 AdVise trial began enrolling in March 2014 and continues to enroll. Immunocompromised patients with asymptomatic, localized, or disseminated adenovirus infection receive brincidofovir for 12 weeks, and are followed for a minimum of 12 weeks after treatment; median observation in this analysis was 10 weeks following the first dose (range: 1 to 34 weeks). Preliminary results from the initial 85 subjects enrolled show a mortality rate of less than 40% for bone marrow transplant recipients with disseminated disease and for the patient population overall. This mortality rate has clinical implications for the potential utility of brincidofovir in this indication as compared with the published mortality rates of up to 80% for transplant recipients with disseminated disease1. Notably, the high-risk transplant recipients who began brincidofovir with localized or asymptomatic adenovirus infection had a preliminary observed mortality rate of 11% (2 of 18 subjects). In addition to these important clinical outcomes, a median 99% decrease in the amount of adenovirus in the blood (viral load) was observed. The preliminary safety and tolerability data in this acutely ill patient population showed a low rate of withdrawal due to brincidofovir-associated adverse events (3/85, 4%), with three patients withdrawing from therapy due to lower gastrointestinal events.

Chimerix Inc. Receives Notice of Allowance from the United States Patent and Trademark Office for its Patent Titled, Nucleoside Phosphonate Salts

ContraVir Pharmaceuticals, Inc. (CTRV) announced that its licensing partner, Chimerix Inc., has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for its patent titled, Nucleoside Phosphonate Salts. The patent covers composition of matter for CMX157, ContraVir's Phase 2-ready, highly potent analog of the successful antiviral drug tenofovir DF (Viread), which ContraVir is developing to treat hepatitis B virus (HBV). The new patent extends ContraVir's intellectual property protection for CMX157 to at least 2031. The extended patent life also provides additional flexibility for the Company to pursue different combination therapies, as well as new development pathways for CMX157. CMX157 is a novel lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate. Its novel structure results in decreased circulating levels of tenofovir, lowering systemic exposure and thereby reducing the potential for renal side effects. A completed Phase 1 clinical trial in healthy volunteers, demonstrated a favorable safety, tolerability and drug distribution profile. In vitro, CMX157 is highly active against HBV and was more than 200-fold more potent as compared to tenofovir against all major HIV subtypes resistant to current therapies. ContraVir licensed CMX157 through a strategic collaboration with Chimerix, Inc. (CMRX) in December 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CMRX:US $40.49 USD +0.01

CMRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bavarian Nordic A/S kr285.00 DKK +73.50
Bioporto A/S kr1.80 DKK -0.03
Celldex Therapeutics Inc $26.37 USD -0.76
Emergent Biosolutions Inc $28.87 USD -1.23
GlaxoSmithKline PLC 1,556 GBp +5.00
View Industry Companies
 

Industry Analysis

CMRX

Industry Average

Valuation CMRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 385.6x
Price/Book 8.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 374.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHIMERIX INC, please visit www.chimerix.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.